Halozyme Therapeutics, Inc. - Common Stock (NQ:HALO)

109.86 +2.92 (+2.73%)

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Halozyme Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

13 14 Next >

Halozyme Therapeutics: A 6.3 Rating and a Future Full of Uncertainty ↗

January 19, 2026

Could Halozyme Therapeutics be the next big opportunity in biotech? Join our experts as they dissect the company's strengths and weaknesses, revealing what investors need to know.

Via The Motley Fool

Q3 Therapeutics Earnings: Halozyme Therapeutics (NASDAQ:HALO) Earns Top Marks

January 18, 2026

Wrapping up Q3 earnings, we look at the numbers and key takeaways for the therapeutics stocks, including Halozyme Therapeutics (NASDAQ:HALO) and its peers.

Via StockStory

Topics Artificial Intelligence

Halozyme Therapeutics Inc (NASDAQ:HALO) Passes Minervini Trend Template and High Growth Momentum Screen ↗

January 17, 2026

Via Chartmill

Halozyme Therapeutics Inc (NASDAQ:HALO) Presents a High-Growth Momentum and Technical Breakout Opportunity ↗

January 13, 2026

Via Chartmill

1 Surging Stock Worth Investigating and 2 We Brush Off

January 11, 2026

The stocks featured in this article are seeing some big returns. Over the past month, they’ve outpaced the market due to some combination of positive news, upbeat results, or supportive macro...

Via StockStory

Halozyme Therapeutics Inc (NASDAQ:HALO) Presents a Compelling Growth at a Reasonable Price (GARP) Case ↗

January 06, 2026

Via Chartmill

HALOZYME THERAPEUTICS INC (NASDAQ:HALO) Presents a Compelling Value Investment Case ↗

December 31, 2025

Via Chartmill

Earnings Scheduled For November 3, 2025 ↗

November 03, 2025

Via Benzinga

Halozyme Therapeutics (HALO): Buy, Sell, or Hold Post Q3 Earnings?

January 07, 2026

Halozyme Therapeutics has had an impressive run over the past six months as its shares have beaten the S&P 500 by 24.3%. The stock now trades at $75.77, marking a 35.8% gain. This was partly due to its...

Via StockStory

Topics Stocks

Q3 Earnings Outperformers: Novavax (NASDAQ:NVAX) And The Rest Of The Therapeutics Stocks

January 04, 2026

Looking back on therapeutics stocks’ Q3 earnings, we examine this quarter’s best and worst performers, including Novavax (NASDAQ:NVAX) and its peers.

Via StockStory

Topics Artificial Intelligence

Halozyme Therapeutics (NASDAQ:HALO) Reports Bullish Q3 CY2025

January 01, 2026

Biopharmaceutical drug delivery company Halozyme Therapeutics (NASDAQ:HALO) reported Q3 CY2025 results exceeding the market’s revenue expectations, with sales up 22.1% year on year to $354.3 million....

Via StockStory

Halozyme Therapeutics (NASDAQ:HALO): A Prime GARP Stock with Strong Growth and Value ↗

December 13, 2025

Halozyme (HALO) exemplifies GARP investing, offering strong growth at a reasonable price with high profitability and a low P/E ratio.

Via Chartmill

The Healthcare Sector Is Surging. Here's 1 Stock Every Investor Should Have on Their Radar. ↗

December 06, 2025

Investing in Halozyme Therapeutics is a compelling way to gain exposure to the broader healthcare and biotechnology industries.

Via The Motley Fool

Topics Intellectual Property

Halozyme Therapeutics Inc (NASDAQ:HALO) Presents a Compelling Case for Value Investors ↗

November 24, 2025

Halozyme (HALO) presents a strong value investment case with a low P/E ratio, high profitability, and solid growth, all at a discounted price.

Via Chartmill

HALOZYME THERAPEUTICS INC (NASDAQ:HALO) Shows Strong Growth Momentum and Bullish Technical Setup ↗

November 21, 2025

HALO stock shows strong EPS & revenue growth with a bullish technical setup, presenting a potential breakout opportunity for momentum investors.

Via Chartmill

Why I Keep Buying These 10 Incredible Growth Stocks ↗

November 17, 2025

These companies have bright futures and offer the potential for decades of share price appreciation.

Via The Motley Fool

Topics Energy

Halozyme Therapeutics Inc (NASDAQ:HALO) Embodies Affordable Growth with Strong Metrics ↗

November 17, 2025

Halozyme Therapeutics offers strong growth and profitability at a reasonable valuation, making it a top Affordable Growth stock pick.

Via Chartmill

Halozyme Therapeutics Inc (NASDAQ:HALO) Shows Strong Technical and Fundamental Momentum ↗

November 14, 2025

Halozyme (HALO) stock shows a powerful uptrend with strong technicals and high-growth fundamentals, including surging earnings and sales.

Via Chartmill

Halozyme Stock Surging On Recent Earnings Beat; Record High Ahead? ↗

November 12, 2025

Halozyme also boasts a 98 Composite Rating out of 99. The best growth stocks have a Composite of 90 or better.

Via Investor's Business Daily

Halozyme Therapeutics Inc (NASDAQ:HALO) Shows Strong Growth and Technical Breakout Potential ↗

November 11, 2025

Discover Halozyme (HALO), a biotech stock with strong EPS growth, high profitability, and a bullish technical breakout pattern for potential gains.

Via Chartmill

Ligand Pharmaceuticals Soars to New Heights: A Deep Dive into its 52-Week High

November 06, 2025

San Diego, CA – November 6, 2025 – Ligand Pharmaceuticals (NASDAQ: LGND) has recently captured the financial spotlight, with its stock hitting a remarkable 52-week high of $197.78 on November 6, 2025....

Via MarketMinute

Topics Intellectual Property

Renaissance Group Opens New $35M Position in Halozyme Therapeutics (NASDAQ: HALO): Why This Biotech Stock Is Worth a Look ↗

November 05, 2025

Renaissance Group Opens New $35M Position in Halozyme Therapeutics (NASDAQ: HALO): Why This Biotech Stock Is Worth a Look

Via The Motley Fool

Topics Regulatory Compliance

Halozyme (HALO) Q3 2025 Earnings Call Transcript ↗

November 03, 2025

Halozyme (HALO) Q3 2025 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

Insights into Halozyme Therapeutics's Upcoming Earnings ↗

October 31, 2025

Via Benzinga

Halozyme Therapeutics Inc (NASDAQ:HALO) Fits a Proven Growth Investing Method ↗

October 30, 2025

Halozyme Therapeutics shows strong growth metrics, including soaring earnings, sales, and a high ROE, fitting a proven growth investing strategy.

Via Chartmill

Koa Wealth Liquidates All 68K IIPR Shares Valued at $3.8 Million ↗

October 29, 2025

Koa Wealth Liquidates All 68K IIPR Shares Valued at $3.8 Million

Via The Motley Fool

Topics Cannabis

HALOZYME THERAPEUTICS INC (NASDAQ:HALO) Combines Strong Growth Momentum with Technical Breakout Setup ↗

October 27, 2025

Halozyme Therapeutics (HALO) offers a high-growth momentum play with strong earnings, rising profit margins, and a technical breakout setup for potential entry.

Via Chartmill

Halozyme Therapeutics Inc (NASDAQ:HALO) Presents a Compelling Value Investment Case ↗

October 25, 2025

Halozyme Therapeutics (HALO) is a strong value stock with high profitability, a healthy balance sheet, and solid growth, all while trading at an attractive valuation.

Via Chartmill

Halozyme Therapeutics Inc (NASDAQ:HALO) Offers an Affordable Growth Profile ↗

October 21, 2025

Halozyme Therapeutics offers strong growth and profitability at an attractive valuation. Its ENHANZE drug delivery tech drives revenue, with a low P/E ratio for an affordable growth stock.

Via Chartmill

Halozyme Therapeutics Inc (NASDAQ:HALO): A Growth Stock Poised for a Breakout ↗

October 18, 2025

Halozyme Therapeutics offers strong growth with high profitability and a positive technical setup, making it a compelling biotech stock to watch.

Via Chartmill

< Previous 1 2 3 4 5 6 7 8 9

...

13 14 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.